Publication | Open Access

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Advanced Breast CancerBreast OncologyOncologyClinical TrialsGynecologyBreast CancerMenopausePharmacotherapyFulvestrant Versus PlaceboCancer TreatmentMenopause Hormone TherapyMedicineRadiation OncologyEndocrine-related CancerWomen's HealthHealth Sciences